EDGEWISE THERAPEUTICS
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders for which there is significant unmet medical need. Guided by its holistic drug discovery approach to targeting the muscle as an organ, Edgewise has combined its foundational expertise in muscle biology and small molecule engineering to build its proprietary, muscle focused drug discovery platform. Edgewiseโs platform utilizes custom-built high throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue, initially focused on addressing rare neuromuscular and cardiac diseases.
EDGEWISE THERAPEUTICS
Social Links:
Industry:
Biopharma Biotechnology Health Care
Founded:
2017-01-01
Address:
Boulder, Colorado, United States
Country:
United States
Website Url:
http://www.edgewisetx.com
Total Employee:
11+
Status:
Active
Contact:
720.262.7002
Email Addresses:
[email protected]
Total Funding:
160.5 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics Google Tag Manager Content Delivery Network Google Universal Analytics Font Awesome
Similar Organizations
Arcutis Biotherapeutics
Arcutis Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing medical dermatology for unmet needs.
Roivant Sciences
Roivant Sciences is a biopharmaceutical company focused on the development of medicines and healthcare technologies to patients.
Wren Therapeutics
Wren Therapeutics is a biopharmaceutical company based, focused on drug discovery and development for protein misfolding diseases.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
New Leaf Ventures
New Leaf Ventures investment in Series C - Edgewise Therapeutics
Viking Global Investors
Viking Global Investors investment in Series C - Edgewise Therapeutics
Cormorant Asset Management
Cormorant Asset Management investment in Series C - Edgewise Therapeutics
OrbiMed
OrbiMed investment in Series C - Edgewise Therapeutics
U.S. Venture Partners
U.S. Venture Partners investment in Series C - Edgewise Therapeutics
Surveyor Capital
Surveyor Capital investment in Series C - Edgewise Therapeutics
CureDuchenne Ventures
CureDuchenne Ventures investment in Series C - Edgewise Therapeutics
Deerfield
Deerfield investment in Series C - Edgewise Therapeutics
Novo Holdings
Novo Holdings investment in Series C - Edgewise Therapeutics
Citadel
Citadel investment in Series C - Edgewise Therapeutics
Official Site Inspections
http://www.edgewisetx.com Semrush global rank: 5.05 M Semrush visits lastest month: 1.64 K
- Host name: a9a78e7bfea26d463.awsglobalaccelerator.com
- IP address: 13.248.152.34
- Location: Seattle United States
- Latitude: 47.6348
- Longitude: -122.3451
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98109
More informations about "Edgewise Therapeutics" on Search Engine
Edgewise Therapeutics - Crunchbase Company Profile & Funding
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization. Boulder, Colorado, United States. 51 โฆSee details»
Pipeline | Edgewise
Our Pipeline. Using our proprietary drug discovery platform, we are developing a pipeline of first in class precision therapeutics that regulate key muscle proteins to address a โฆSee details»
Company | Edgewise
Our Vision. Our vision is to improve the lives of patients and families suffering from rare muscle disorders by building the worldโs leading muscle-focused, precision medicine company. Key components of our strategy to achieve this vision include:See details»
Edgewise Therapeutics, Inc. - Investor Relations
Corporate Profile. Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments โฆSee details»
Edgewise Receives U.S. FDA Fast Track Designation for EDG โฆ
BOULDER, Colo., February 13, 2024 -- ( BUSINESS WIRE )--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today โฆSee details»
Clinical Trials | Edgewise
Edgewise is committed to developing new therapies for people living with severe, genetic neuromuscular or cardiac disorders. Novel therapies require years of laboratory โฆSee details»
A Novel Approach to Tackling Rare Progressive Muscle Disorders
Edgewise Therapeutics is a Clinical-Stage Company Focused on Advancing Innovative Treatments for Severe, Rare Muscle Disorders . 3. Plan to enhance portfolio from โฆSee details»
Edgewise Therapeutics Begins Dosing First-in-Human
Sep 14, 2023 Edgewise Therapeutics is a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac โฆSee details»
Areas of Focus | Edgewise
With our novel drug discovery platform, and our combined expertise in muscle physiology and small molecule drug design, Edgewise Therapeutics is working to change the future. Edgewise is currently โฆSee details»
Edgewise Therapeutics Announces Positive Two-Year Topline
Apr 15, 2024 Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced positive two-year topline results from the โฆSee details»
Edgewise Therapeutics - Funding, Financials, Valuation & Investors
Edgewise Therapeutics is registered under the ticker NASDAQ:EWTX . Their stock opened with $16.00 in its Mar 26, 2021 IPO. Edgewise Therapeutics is funded by 15 โฆSee details»
Edgewise Therapeutics Reports Fourth Quarter and Full Year โฆ
Feb 22, 2024 Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today reported financial results for the fourth quarter and โฆSee details»
Edgewise Therapeutics Announces Positive Two-Year Topline โฆ
BOULDER, Colo., April 15, 2024 -- ( BUSINESS WIRE )--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today โฆSee details»
2024-04-23 | NDAQ:EWTX | Press Release | Edgewise โฆ
4 days ago About Edgewise Therapeutics. Edgewise Therapeutics is a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular โฆSee details»
Edgewise Therapeutics Announces Initiation of GRAND โฆ
Sep 26, 2023 BOULDER, Colo.โ (BUSINESS WIRE)โ Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today โฆSee details»
Edgewise Therapeutics - Contacts, Employees, Board Members, โฆ
Organization. Edgewise Therapeutics. Connect to CRM. Summary Financials People Technology Signals & News Similar Companies. Highlights. Employee Profiles 8. โฆSee details»
Edgewise Therapeutics to Present on EDG-5506 for the โฆ
BOULDER, Colo., February 28, 2024--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that the โฆSee details»
EDGEWISE THERAPEUTICS ANNOUNCES POSITIVE TWO โฆ
Apr 16, 2024 Edgewise Therapeutics Announces Positive Two-Year Topline Results from the ARCH Open Label Trial of Sevasemten (EDG-5506) in Adults with Becker โฆSee details»
Edgewise Therapeutics, Inc. - Governance - Board of Directors
Edgewise Therapeutics, Inc. - Governance - Board of Directors. Board of Directors. Peter Thompson, M.D. Chairman and Co-Founder. Peter Thompson, M.D., serves as a โฆSee details»
Series C - Edgewise Therapeutics - 2020-12-08 - Crunchbase
Dec 8, 2020 Overview. Organization Name. Edgewise Therapeutics. Announced Date Dec 8, 2020. Funding Type Series C. Funding Stage Late Stage Venture. Money Raised. $95M. Pre-Money Valuation $200M. Lead Investors.See details»